Evidence map›Paper›PMID 26310943›Full record

ArticleBMC public health2015

Treatment outcomes and their determinants in HIV patients on Anti-retroviral Treatment Program in selected health facilities of Kembata and Hadiya zones, Southern Nations, Nationalities and Peoples Region, Ethiopia.

Wondimu Ayele, Afework Mulugeta, Alem Desta, Felicia A Rabito

Abstract readMulticenter Study
In one paragraph

Article in BMC public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wondimu AyeleSchool of Public Health, Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia. wondaay@gmail.com.
Afework MulugetaDepartment of Public Health, Mekelle University, Mekelle, Ethiopia. afework.mulugeta@gmail.com.
Alem DestaDepartment of Public Health, Mekelle University, Mekelle, Ethiopia. wuneha@gmail.com.
Felicia A RabitoDepartment of Public Health, Tulane University, New Orleans, LA, USA. rabito@tulane.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEthiopia has been providing free Antiretroviral Treatment (ART) since 2005 for HIV/AIDS patients. ART improves survival time and quality of life of HIV patients but ART treatment outcomes might be affected by several factors. However, factors affecting treatment outcomes are poorly understood in Ethiopia. Hence, this study assesses treatment outcomes and its determinants for HIV patients on ART in selected health facilities of Kembata and Hadiya zones.

methodsA retrospective cohort study was conducted on 730 adult HIV/AIDS patients who enrolled antiretroviral therapy from 2007 to 2011 in four selected health facilities of Kembata and Hadiya zones of Southern Ethiopia. Study subjects were sampled from the health facilities based on population proportion to size. Data was abstracted using data extraction format from medical records. Kaplan-Meier survival function was used to estimate survival probability. Cox proportional hazards regression model was used to identify factors associated with time to death.

resultMedian age of patients was 32.4 years with Inter Quartile Range (IQR) [15, 65]. The female to male ratio of the study participants' was 1.4:1. Median CD4 count significantly increased during the last four consecutive years of follow up. A total of 92 (12.6%) patients died, 106(14.5%) were lost to follow-up, and 109(15%) were transferred out. Sixty three (68%) deaths occurred in the first 6 months of treatment. The median survival time was 25 months with IQR [9, 43]. After adjustment for confounders, WHO clinical stage IV [HR 2.42; 95% CI, 1.19, 5.86], baseline CD4 lymphocyte counts of 201 cell/mm(3) and 350 cell/mm(3) [HR 0.20; 95 % CI; 0.09-0.43], poor regimen adherence [HR 2.70 95% CI: 1.4096, 5.20], baseline hemoglobin level of 10 gm/dl and above [HR 0.23; 95% CI: 0.14, 0.37] and baseline functional status of bedridden [HR 3.40; 95% CI: 1.61, 7.21] were associated with five year survival of HIV patients on ART.

conclusionAll people living with HIV/AIDS should initiate ART as early as possible. Initiation of ART at the early stages of the disease, before deterioration of the functional status of the patients and before the reduction of CD4 counts and hemoglobin levels with an intensified health education on adherence to ART regimen is recommended.

Indexed as

AdultAgedAge DistributionAnti-HIV AgentsCD4 Lymphocyte CountEthiopiaFemaleHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsQuality of LifeRetrospective StudiesSex DistributionAnti-HIV Agents

Identifiers

PMID26310943
PMCPMC4549910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.